Taher Abu Hejleh

Summary

Affiliation: University of Iowa
Country: USA

Publications

  1. doi request reprint Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers
    Taher Abu-Hejleh
    Department of Internal Medicine, Division of Hematology, Oncology, and Bone Marrow Transplantation, The University of Iowa Hospitals and Clinics, 200 Hawkins Dr, C32 GH, Iowa City, IA 52242 1081, USA
    Curr Oncol Rep 14:277-84. 2012
  2. ncbi request reprint Advances in the systemic treatment of leptomeningeal cancer
    Taher Abu Hejleh
    Division of Hematology, Oncology and Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1081, USA
    Clin Adv Hematol Oncol 10:166-70. 2012

Collaborators

  • Taher Abu-Hejleh
  • Thorvardur R Halfdanarson
  • Michael J Goodheart
  • James J Mezhir

Detail Information

Publications2

  1. doi request reprint Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers
    Taher Abu-Hejleh
    Department of Internal Medicine, Division of Hematology, Oncology, and Bone Marrow Transplantation, The University of Iowa Hospitals and Clinics, 200 Hawkins Dr, C32 GH, Iowa City, IA 52242 1081, USA
    Curr Oncol Rep 14:277-84. 2012
    ..The management of bevacizumab-induced bowel perforation depends on the clinical presentation and the goals of care set by the treating physicians and the patient...
  2. ncbi request reprint Advances in the systemic treatment of leptomeningeal cancer
    Taher Abu Hejleh
    Division of Hematology, Oncology and Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1081, USA
    Clin Adv Hematol Oncol 10:166-70. 2012
    ..In this article, we review the history of the major therapeutic approaches used to treat LMC, and we expand on the promising new venues for applying biologic targeted agents to the treatment options utilized in LMC...